Business
Citius Pharmaceuticals Announces Key Management Realignment to Support Commercialization of Two Late-Stage Product Candidates
Leonard Mazur named Chairman of the Board of Directors and CEO of Citius Citius co-founder, Myron Holubiak to transition from President & CEO to Executive
About this update from Citius Pharmaceuticals, Inc.
[{"type":"text","content":"Leonard Mazur named Chairman of the Board of Directors and CEO of Citius\nCitius co-founder, Myron Holubiak to transition from President & CEO to Executive Vice Chairman of the Board of Directors to build commercial capabilities, effective May 1, 2022\nJaime Bartushak, Chief Financial Officer, to assume additional responsibilities as Chief Business Officer\nCommercial capabilities strengthened with addition of Michael McGuire as VP, Program Leader for Anti-Infectives\nCRANFORD, N.J., April 13, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (\"Citius\" or the \"Company\") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that the Board of Directors has approved key management changes to strengthen the Company's commercial capabilities as its two late Phase 3 programs for I/ONTAK (E7777) and Mino-Lok® near completion. The organizational alignment will enable Citius to focus its resources on advancing both of these near-term opportunities and will be effective as of May 1, 2022.\nThe Board of Directors has appointed Mr. Holubiak to the newly created position of Executive Vice Chairman with responsibility for building the Citius commercial team and guiding the anticipated product launches of the Company's first commercial products. Mr. Holubiak will drive the overall commercial strategy in support of the Citius pipeline. The near-term focus will be on the successful launch of I/ONTAK for the systemic treatment of cutaneous T-cell lymphoma (CTCL), which recently released topline results from its Phase 3 trial, and Mino-Lok® which is expected to complete Phase 3 trial enrollment later this year. Leonard Mazur, Citius co-founder and Executive Chairman has been named as CEO and Chairman by the Board of Directors. Additionally, in recognition of the incremental needs of a growing Citius team, Chief Financial Officer Jaime Bartushak will assume additional responsibilities as Chief Business Officer.\n\"Myron and I co-founded Leonard Meron Biosciences, which ultimately merged with Citius, to bring life-altering therapies to patients in need. He continues to be an outstanding partner and dedicated CEO...